KPP Advisory Services LLC Has $670,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

KPP Advisory Services LLC raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 17.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,196 shares of the company’s stock after buying an additional 1,675 shares during the quarter. KPP Advisory Services LLC’s holdings in Apellis Pharmaceuticals were worth $670,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its position in shares of Apellis Pharmaceuticals by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 904,409 shares of the company’s stock worth $54,138,000 after buying an additional 25,052 shares during the period. Norges Bank bought a new position in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $56,640,000. Wynnefield Capital Inc. bought a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $380,000. Great Lakes Advisors LLC bought a new position in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $12,461,000. Finally, abrdn plc bought a new position in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $10,119,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ APLS traded down $0.68 during trading hours on Friday, hitting $40.37. The company had a trading volume of 508,744 shares, compared to its average volume of 1,189,230. The stock has a market capitalization of $4.90 billion, a P/E ratio of -11.67 and a beta of 0.95. The company has a quick ratio of 3.02, a current ratio of 3.77 and a debt-to-equity ratio of 0.35. Apellis Pharmaceuticals, Inc. has a 1-year low of $19.83 and a 1-year high of $94.75. The firm’s 50 day moving average is $46.50 and its 200-day moving average is $56.48.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). Apellis Pharmaceuticals had a negative return on equity of 160.77% and a negative net margin of 79.67%. The business had revenue of $172.33 million for the quarter, compared to analysts’ expectations of $163.37 million. During the same quarter in the prior year, the business earned ($1.56) EPS. The firm’s revenue for the quarter was up 284.3% on a year-over-year basis. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on APLS shares. UBS Group cut their price objective on Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. HC Wainwright reiterated a “buy” rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, May 28th. Piper Sandler assumed coverage on Apellis Pharmaceuticals in a report on Friday, May 31st. They set a “neutral” rating and a $46.00 price objective on the stock. Wells Fargo & Company cut their target price on Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 23rd. Finally, Citigroup cut their target price on Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $74.38.

Insider Activity at Apellis Pharmaceuticals

In related news, CFO Timothy Eugene Sullivan sold 4,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $58.66, for a total value of $234,640.00. Following the sale, the chief financial officer now owns 93,338 shares in the company, valued at approximately $5,475,207.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Apellis Pharmaceuticals news, insider Mark Jeffrey Delong sold 9,913 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $56.90, for a total transaction of $564,049.70. Following the transaction, the insider now owns 54,693 shares in the company, valued at approximately $3,112,031.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Timothy Eugene Sullivan sold 4,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $58.66, for a total value of $234,640.00. Following the transaction, the chief financial officer now owns 93,338 shares in the company, valued at approximately $5,475,207.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 192,012 shares of company stock worth $9,608,319. Company insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).